Baird analyst David Rescott raised the firm’s price target on Medtronic (MDT) to $96 from $94 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results where PFA upside offset oher downsides on MSD growth.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $98 from $97 at Bernstein
- Medtronic’s Strong Financial Performance and Positive Outlook Justify Buy Rating
- Medtronic price target raised to $100 from $98 at Wells Fargo
- Positive Outlook for Medtronic Amid Strategic Changes and Elliott Management Investment
- Medtronic Reports Strong Q1 FY26 Results